



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

16th September 2024

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that the Company has received an Order dated 31st May 2024 for period FY 2017-18 to 2021-22 from Telangana Commissioner of Customs and Central Tax (Appeals-II), raising total demand of Rs.1,07,16,991 in Telangana State. The relevant details to be disclosed is as under:

Sr no	Particulars	Details
1	Name of the authority	Commissioner of Central tax & GST (Appeals-II), Office of the Commissioner of Central tax & GST (Appeals-II), Hyderabad
2	Nature and details of the action(s) taken, initiated or order(s) passed	Order dated 31 st May 2024 passed under Section 73 & 74 of CGST Act, 2017. Tax of Rs.91,76,555, Interest Not quantified and Penalty of Rs.15,40,436/-
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	13 th September 2024
4	Details of violation(s) / contravention(s) committed or alleged to be committed	The officer has raised demand majorly in relation to GST credit related issues (mismatch between Company's GST returns vis-à-vis details reported by suppliers) and disallowance of GST credit attributable to GST credit notes issued to customers
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	No impact on GSK. The Company believes that the said demand is not maintainable and in the process of preferring to file an Appeal against the said Order

Note: The above Order has been received by the Company on 13th September 2024, i.e. on Friday evening due to which, the above disclosure is being made today.

Kindly take the same on the record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151